Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.
CRISPR Therapeutics (NASDAQ: CRSP) has reached a very exciting point in its story. The biotech company that specializes in gene editing is awaiting regulatory decisions on what could become its first commercialized product. The U.S. Food and Drug Administration (FDA) is set to rule on exa-cel for sickle cell disease next month and exa-cel for beta thalassemia in March. And regulators in the U.K. and Europe also are considering the blood disorders candidate.
Meanwhile, shares of CRISPR Therapeutics have climbed about 39% this year -- but they still are far from their peak level, reached in 2021.
So, investors who have been watching CRISPR Therapeutics, or even holding the shares for a while, may be wondering if the stock has any chance of returning to those highs or making it part of the way. Could this dynamic biotech stock double in five years? It's possible -- here's what it would take.
Source Fool.com
